期刊
BMC VETERINARY RESEARCH
卷 17, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12917-021-02927-5
关键词
Flucytosine; Fluorouracil; Drug-related side effects; Adverse reactions; Pharmacokinetic; Dog; Targeted chemotherapy; Antineoplastic agents
Long-term administration of 5-fluorocytosine in healthy dogs resulted in cutaneous toxicity, indicating that pharmacotherapy should be adjusted to reduce toxicity in targeted chemotherapy.
Background 5-fluorocytosine is a pyrimidine and a fluorinated cytosine analog mainly used as an antifungal agent. It is a precursor of 5-fluorouracil, which possesses anticancer properties. To reduce systemic toxicity of 5-fluorouracil during chemotherapy, 5- fluorocytosine can be used as a targeted anticancer agent. Expression of cytosine deaminase by a viral vector within a tumor allows targeted chemotherapy by converting 5-fluorocytosine into the cytotoxic chemotherapeutic agent 5-fluorouracil. However, little is known about the tolerance of 5-fluorocytosine in dogs after prolonged administration. Results In three healthy Beagle dogs receiving 100 mg/kg of 5-fluorocytosine twice daily for 14 days by oral route, non-compartmental pharmacokinetics revealed a terminal elimination half-life of 164.5 +/- 22.5 min at day 1 and of 179.2 +/- 11.5 min, after 7 days of administration. Clearance was significantly decreased between day 1 and day 7 with 0.386 +/- 0.031 and 0.322 +/- 0.027 ml/min/kg, respectively. Maximal plasma concentration values were below 100 mu g/ml, which is considered within the therapeutic margin for human patients. 5-fluorouracil plasma concentration was below the limit of detection at all time points. The main adverse events consisted of depigmented, ulcerated, exudative, and crusty cutaneous lesions 10 to 13 days after beginning 5-fluorocytosine administration. The lesions were localized to the nasal planum, the lips, the eyelids, and the scrotum. Histological analyses were consistent with a cutaneous lupoid drug reaction. Complete healing was observed 15 to 21 days after cessation of 5-fluorocytosine. No biochemical or hematological adverse events were noticed. Conclusions Long term administration of 5-fluorocytosine was associated with cutaneous toxicity in healthy dogs. It suggests that pharmacotherapy should be adjusted to reduce the toxicity of 5-fluorocytosine in targeted chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据